What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-08-05 compared with 2025-04-29 · 44 added, 28 removed, 84 unchanged (46% of the section changed)

3 unchanged sentences

On March 31, 2025 , Thomas Trimarchi , our President and Chief Financial Officer , adopted a trading plan (the “Trimarchi Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c).

The Trimarchi Trading Plan provides for the potential sale of a maximum of (i) 47,887 shares of our common stock held by Dr.

Trimarchi and (ii) 100% of net vested shares of our common stock to be issued to Dr.

Trimarchi upon vesting of his restricted stock units (“RSUs”) on

May 16, 2025.

On the date when the Trimarchi Trading Plan was adopted, Dr.

Trimarchi held no such net vested shares.

Trimarchi’s net vested share amount will change as additional RSUs vest on the applicable vesting date.

The aggregate number of net vested shares of common stock that will be available for sale by Dr.

Trimarchi is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of his RSUs on the vesting date.

Trimarchi is not permitted to transfer, sell or otherwise dispose of any shares under the Trimarchi Trading Plan during the 90-day period following the plan’s adoption.

The Trimarchi Trading Plan is expected to remain in effect until the earlier of (1) May 29, 2026 and (2) the date on which all transactions under such plan have been completed.

On March 31, 2025 , Dr.

Neil Kumar , our Chief Executive Officer and a member of our Board of Directors, adopted a new trading plan (the “Kumar Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) on behalf of himself and Kumar Haldea Revocable Trust and Kumar Haldea Family Irrevocable Trust, of which Dr.

Kumar is a co-trustee.

The Kumar Trading Plan provides for the potential sale of a maximum of (i) 480,000 shares of our common stock held by Kumar Haldea Family Irrevocable Trust, (ii) 480,000 shares of our common stock held by Kumar Haldea Revocable Trust, and (ii) 100% of net vested shares of our common stock to be issued to Dr.

Kumar upon vesting of his RSUs on August 16, 2025, November 16, 2025, December 10, 2025, February 16, 2026 and May 16, 2026.

On the date when the Kumar Trading Plan was adopted, Dr.

Kumar held no such net vested shares.

Kumar’s net vested share amount will change as additional RSUs vest on each of these vesting dates.

On May 8, 2025 , Dr.

Homcy , a member of our Board of Directors , adopted a trading plan (the “Homcy Trading Plan”) in tended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) for the potential sale of a maximum of 300,000 shares of our common stock.

Homcy is not permitted to transfer, sell or otherwise dispose of any shares under the Homcy Trading Plan until the Earliest Sell Date, which is the later of (i) the 91st day after the adoption date of the Homcy

Trading Plan;

or (ii) the earlier of:

(a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Homcy Trading Plan is adopted;

or (b) the 121st day after the adoption date.

The Homcy Trading Plan is expected to remain in effect until the earlier of (a) March 8, 2026 ;

(b) the first date on which all trades have been executed or all trading orders relating to such trades set forth on Addendum A of the Homcy Trading Plan have expired;

Homcy gives written notice to Morgan Stanley Smith Barney LLC (“MSSB”) to terminate the Homcy Trading Plan;

(d) as soon as practicable following the date on which MSSB receives written notice of a termination of an additional contract, instruction or plan that is being treated as a single “plan” with the Homcy Trading Plan (or MSSB receives written notice of a modification of such additional contract, instruction or plan and the requirements for a modification of the Homcy Trading Plan are not or cannot be satisfied);

(e) as soon as practicable following the date on which MSSB receives written notice of a legal, regulatory or contractual restriction applicable to the Company or to Dr.

Homcy that would result in a modification or change to the amount, price or timing of the sale of shares under the Homcy Trading Plan but the requirements for a modification of the Homcy Trading Plan are not or cannot be satisfied;

and (f) as soon as practicable following the date on which MSSB receives notice of certain events, including the public announcement of a tender or exchange offer with respect to the Company’s common stock or that the Company is the target of a merger, acquisition, reorganization, recapitalization or comparable transaction as a result of which the Company’s common stock will be converted into shares of another company, or the commencement of bankruptcy or insolvency proceeding with respect to the Company.

On June 27, 2025 , Randal W.

Scott, Ph.D ., a member of our Board of Directors , adopted a trading plan (the “Scott Trading Plan”), intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c).

The Scott Trading Plan provides for the potential sale of a maximum of (i) 51,501 shares of our employee stock options held by Dr.

Scott, and (ii) 100% of net vested shares of our RSUs to be issued to Dr.

Scott upon vesting of his RSUs on June 20, 2026.

On the date when the Scott Trading Plan was adopted, Dr.

Scott held no such net vested shares.

The aggregate number of net vested shares of common stock that will be available for sale by Dr.

Kumar is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of his RSUs on each of these vesting dates.

Kumar is not permitted to transfer, sell or otherwise dispose of any shares under the Kumar Trading Plan during the 90-day period following the plan’s adoption.

The Kumar Trading Plan is expected to remain in effect until the earlier of (1) June 5, 2026 and (2) the date on which all transactions under such plan have been completed.

Scott is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of his RSUs on the vesting date.

Scott is not permitted to transfer, sell or otherwise dispose of any shares under the Scott Trading Plan until the later of (i) November 17, 2025, (ii) the 91st day after the adoption date of the Scott Trading Plan (i.e.

September 26, 2025), or (iii) the earlier of:

(a) the third business day following the disclosure of the Company’s financial results in a Form 10-Q or Form 10-K for the completed fiscal quarter in which the Scott Trading Plan is adopted (estimated August 7, 2025);

or (b) the 121 st day after the adoption date of the Scott Trading Plan (estimated October 26, 2025).

The Scott Trading Plan is expected to remain in effect until the earlier of (a) August 31, 2026 ;

(b) the completion of the sale of the maximum shares subject to the Scott Trading Plan.

Exhibit Title

4 unchanged sentences

Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect .

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant

June 23, 2025

Amended and Restated Bylaws of the Registrant, as currently in effect .

24 unchanged sentences

February 28, 2025

Consulting Agreement, dated March 17, 2025, between BridgeBio Pharma, Inc.

and Brian Stephenson.

Royalty Interest Purchase and Sale Agreement, dated June 27, 2025, by and among BridgeBio Pharma, Inc.

Acoramidis Royalty SPV, LP and LSI Financing Fund, LP

Filed herewith

First Amendment to Funding Agreement, dated as of June 27, 2025, by and among LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.À R.L.

as Purchasers, the BridgeBio Pharma, Inc.

and certain subsidiaries of BridgeBio Pharma, Inc.

as Seller Parties, and Alter Domus (US) LLC as Collateral Agent.

Filed herewith

BridgeBio Pharma, Inc.

Second Amended and Restated 2021 Stock Option and Incentive Plan and form award agreements thereunder

June 23, 2025

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .

33 unchanged sentences

BridgeBio Pharma, Inc.

April 29, 2025

August 5, 2025

/s/ Neil Kumar

2 unchanged sentences

(Principal Executive Officer)

April 29, 2025

August 5, 2025

/s/ Thomas Trimarchi

2 unchanged sentences

(Principal Financial Officer)

April 29, 2025

August 5, 2025

/s/ Maricel M.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information